Biophan Technologies Receives Additional U.S. Nanotechnology Patent; Expands Comprehensive Coverage of MRI Safety, Compatibility, and Drug Delivery.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, announced today the issuance of Patent No. 6,864,418, "Nanomagnetically Shielded Substrate," by the U.S. Patent and Trademark Office on March 8th of this year, expanding the patent coverage over nanomagnetic materials that is licensed from Nanoset, LLC to Biophan. This patent has applications in medical device technology being developed for commercial use by Biophan to protect patients having pacemakers and other similar implanted devices from potential harm due to magnetic resonance imaging (MRI) one of medicine's most important diagnostic imaging tools.

This patent focuses on the nanoscale composition, structure, and tuning of nanomagnetic shielding materials, and the effects these design properties have on the way the shield coating performs in the complex and powerful electromagnetic fields used in MRI. These specialized properties can be engineered to provide shielding for medical devices that are tuned to protect against these MRI-related electromagnetic fields.

The issuance of this patent brings Biophan's total issued patents to 33, in addition to 75 applications in process, for a total of 108 issued and pending U.S. applications, plus international coverage.

"We are developing what is known in the intellectual property community as extensive patent thickets, providing extensive coverage of solutions in this broad market arena. Biophan is achieving its strategic goal of cornering the market for MRI safe and image compatible implantable medical devices and interventional surgical instruments. As the industry transitions to this capability, and as devices and surgical tools begin shipping, this patent portfolio will become increasingly more important," stated Michael Weiner, CEO of Biophan.

Nanoset, LLC, an East Rochester, New York technology developer working with Biophan, has filed multiple new patents for the use of nanomagnetic particles. These technologies can be used to reduce image artifacts on implantable and interventional medical devices and for a new class of applications to enhance the uptake, release, and monitoring of drugs in medical device coatings. Biophan holds the worldwide exclusive rights to all medical applications developed by Nanoset.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 108 U.S. patents, licenses, or applications. This total includes 33 issued U.S. patents, 7 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.